Navigation Links
A drug combination extends survival in refractory lung cancer patients
Date:6/2/2011

NEW YORK CITY Scientists have identified a drug combination, when used in advanced lung cancer patients, shows a survival advantage in patients who no longer respond to existing therapies. They found that bexarotene and erlotinib can each repress the critical cell cycle regulator: cyclin D1. The drug combination also broadened the reach to include a specific subset of patients, such as those resistant due to the presence of a ras mutation in their cancer. The study was published in the June issue of Cancer Prevention Research.

"Erlotinib has been found to be most effective in women of Asian descent who are never smokers with bronchioalveolar carcinoma, and who tend to have activating mutations of the epidermal growth factor receptor," said Ethan Dmitrovsky, M.D., an Associate Scientific Director of the Samuel Waxman Cancer Research Foundation and a senior author on the study. "None of the patients in our study fit that demographic profile."

In fact, the patients in the cohort who exhibited the greatest response included non-Asian men who were smokers. Advanced lung cancer patients with refractory disease have a survival of four months or less with traditional chemotherapy. The results of the study showed a median survival of five and a half months and longer. Three patients from the trial are now living two to four years beyond the expected average.

The study's results were recently duplicated by a group of MD Anderson scientists, noted Konstantin Dragnev, M.D., who led this trial and is an associate professor at Dartmouth Medical School, in Hanover, N.H.

The most exciting part of the research, which was funded in part by the Samuel Waxman Cancer Research Foundation, "is that scientists were able to make a dent in the ras mutation subset of patients," said Dmitrovsky, who is a professor at Dartmouth Medical School. "This area is an unmet medical need. These are often times the most difficult lung cancers to treat."

"This study gives hope to a large group of lung cancer patients who currently have very few options," said Linda Wenger, the Executive Director of Uniting Against Lung Cancer. "It's critical for nonprofit foundations to continue supporting research in underserved areas to bring new ideas to the clinic."


'/>"/>

Contact: Jenny Song
jsong@waxmancancer.org
646-398-5277
Samuel Waxman Cancer Research Foundation
Source:Eurekalert

Related biology news :

1. Old stain in a new combination
2. Diabetes drug kills cancer stem cells in combination treatment in mice
3. Investigators identify cleat/natural grass combination may be less likely to result in ACL injury
4. Study: Grass, fungus combination affects ecology
5. Grape news: New treatment combination safe alternative to sulfur dioxide
6. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
7. Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer
8. Combination therapy reduced HER2-positive breast cancers
9. Killing drug-resistant melanoma requires combination therapy
10. Combination therapy provides hope for cure of dangerous infections of cystic fibrosis patients
11. Microbubble-delivered combination therapy eradicates prostate cancer in vivo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
(Date:3/16/2017)... Germany , March 16, 2017 CeBIT 2017 - Against identity ... Continue Reading ... Used combined in one project, multi-biometric solutions provide ... Used ... Systems) ...
Breaking Biology News(10 mins):
(Date:4/28/2017)... ... April 28, 2017 , ... KCAS ... validated a 0.2 ng/mL lower limit (LLOQ) assay for nicotine and two key ... assay, the ultra-low trace nicotine assay meets additional needs of tobacco industry that ...
(Date:4/27/2017)... ... April 27, 2017 , ... This month ... (eConsent) solution that simplifies research studies, accelerates study startup, and improves participant engagement. ... Consent™ is the first and only IRB-integrated eConsent solution . , “Our ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... and photonics , joined other scientists, researchers, engineers, and industry professionals in visiting ... strengthen America's ability to compete in the world photonics industry. , This year, ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... with NASA to showcase the future of deep space exploration and inspire space ... and Orion spacecraft and includes a guest appearance by former Shuttle Astronaut Don ...
Breaking Biology Technology: